COR 817
Alternative Names: COR-817Latest Information Update: 01 Aug 2022
At a glance
- Originator Cortexyme
- Developer Quince Therapeutics
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Coronavirus infections